KalVista Pharma (KALV) Stock Forecast & Price Target

KalVista Pharmaceuticals Inc. has demonstrated strong early demand for its FDA-approved product EKTERLY (sebetralstat), with 460 start forms within the first eight weeks of launch, highlighting its potential to capture around $31 million in revenue, contingent on patient treatment and access to payers. The company ended the quarter with a robust cash position of $191 million, providing financial stability and operational runway into 2027, which is critical for supporting its growth strategy. Although the on-demand hereditary angioedema (HAE) market is mature, KalVista's differentiated offerings and strong early uptake may position it for favorable market penetration and long-term success.

KalVista Pharmaceuticals faces significant financial challenges, primarily due to the reliance on the performance of its product sebetralstat; failure or underperformance in its early launch phase could jeopardize the company's growth prospects as its current pipeline offers limited alternatives. The company is projected to continue incurring net losses, with operational expenses exceeding consensus estimates, raising concerns about financial sustainability in the near term. Additionally, uncertainty surrounding the phase 3 trial results for deucrictibant has created a notable overhang on the stock, contributing to a high short interest and making consensus estimates unreliable as the market recalibrates expectations.